Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial
BMC Medicine, 2025
Zhao X., Zhang J., Qiu L., Han Q., Yan X., Zhu Y., Wang J., Zhang X., Jiao S., Sun S.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Immunotherapy | Patient Stratification | Serum |  Olink Target 48 |
Abstract
Background
Extensive-stage small cell lung cancer (ES-SCLC) is characterized by a high risk of malignancy and a poor prognosis. This trial aimed to evaluate the efficacy and safety of envafolimab plus chemotherapy as a first-line treatment for ES-SCLC.
Methods
This prospective, single-arm, phase II trial was conducted at the Fifth Medical Center of Chinese PLA General Hospital. Eligible patients with histologically or cytologically confirmed ES-SCLC were consecutively enrolled. Patients were given four cycles of carboplatin (area under the curve of 5–6 mg/mL/min, day 1 of each cycle) and etoposide (80–100 mg/m2 of body-surface area, on day 1–3 of each cycle) with envafolimab (300 mg, Q3W, day 3 post-chemotherapy of each cycle), followed by envafolimab maintenance until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS).
Results
Between October 2021 and November 2022, a total of 32 patients were enrolled in this trial. A total of 32 patients were included in the safety analysis, and 31 patients were included in the efficacy analysis. As of the data cutoff (September 15, 2024), the median follow-up was 27.7 months (IQR, 22.6–NA). The objective response rate (ORR) was 87.1% (95% CI, 70.2–96.4%), and the disease control rate (DCR)was 100% (95% CI, 88.8–100%). The median duration of response (DoR) was 5.47 months (95% CI, 3.43–10 months). The median progression-free survival (PFS) was 6.43 months (95% CI, 4.83–7.67 months), and median overall survival (OS) was 20 months (95% CI, 14.7–NA). Treatment-related adverse events (TRAEs) of any grade were reported in 59.4% of patients, with grade ≥ 3 TRAEs reported in 15.6% of patients. No treatment-related deaths occurred. Additionally, findings from serum proteomic profiling demonstrated that specific immune-related proteins, including CCL3, CXCL10, HGF, and CXCL8, might be correlated with shorter survival and worse clinical outcomes.
Conclusions
Envafolimab combined with chemotherapy as a first-line treatment for ES-SCLC yielded favorable clinical efficacy with a manageable safety profile, indicating that it may be a promising treatment modality.